Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363647 · ClinicalTrials.gov registry record · NA
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02363647 is a NA study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 10 participants.
The verdict
NCT02363647, a NA study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The Personalized Discovery Process is the only program offering patients treatment recommendations based on an empirically constructed Drosophila "fly" model of their disease. Special committee selects one of the one of the few 2-3 FDA approved drug combinations or single agents that improved survival in the fly cancer model.
Interventions
- OTHER Tumor Genomic Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-01 |
| Est. Completion | 2022-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02363647
The ClinicalTrials.gov registry entry for NCT02363647 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor Genomic Analysis is the first listed.
NCT02363647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02363647 about?
NCT02363647 is a clinical study titled "Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer". The Personalized Discovery Process is the only program offering patients treatment recommendations based on an empirically constructed Drosophila "fly" model of their disease. Special committee selects one of the one of the few 2-3 FDA approved drug combinations or single agents that improved surviv...
What is the current status of trial NCT02363647?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2022-08.
What interventions are being tested in trial NCT02363647?
The interventions under investigation include: Tumor Genomic Analysis (OTHER).
Who is sponsoring clinical trial NCT02363647?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.